You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Luminal Vascular Coating to Prevent Intimal Hyperplasia Following Creation of a
SBC: Symic Bio, Inc. Topic: NIDDKDESCRIPTION (provided by applicant): This proposal addresses PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]). More than 20 million American adults (1 in 10) have some level of chronic kidney disease (CDC), with a growing incidence in the aging population. Nearly 400,000 ESRD patients receive some form of dialysis, with t ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS
SBC: XFIBRA, LLC Topic: NIDDKDESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearance by apoptosis may allow recovery from liver injury andreversal of liver fibrosis. There is full agreement among liver fibrosis experts that inhibiting o reversing HS activation (the therapeutic targ ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis
SBC: DYNAVAX TECHNOLOGIES CORPORATION Topic: NIDDKDESCRIPTION (provided by applicant): Hepatic fibrosis (HF) is a major health problem leading to cirrhosis and death. There is currently no pharmacological treatment for HF, and liver transplantation is unable to meet the needs of all patients afflicted with HF. We have shown that chronic liver injury involves the activation of Toll-like receptor 7 (TLR7) and TLR9. We further demonstrated that the ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of OCT Imaging Adapter for Interstitial Tissue Imaging
SBC: WEST FACE MEDICAL DEVICES, INC. Topic: NIBIBDESCRIPTION (provided by applicant): This Phase I STTR Grant Proposal requests 100,000 support for WestFace Medical Device to construct and test the WestFace Imaging Adaptor in conjunction with Ruikang K. Wang, PhD and his laboratory at the University ofWashington. Utilizing optical coherence tomography (OCT), the patented OCT Adaptor (USPTO Pats. # 7,682,089, # 8,057,107, #8,235,602) provides re ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Single Cell chemical Imaging via nanoscale IR ablation- Mass Spectromety
SBC: Anasys Instruments Corp. Topic: NIGMSDESCRIPTION (provided by applicant): The goals of this project are twofold: a) to develop a new technique for nanoscale Mass spectrometry imaging based on AFM based tip enhanced IR ablation (nanoIR-MS). b) to apply this technique towards the application ofSingle cell imaging. Information on the chemical composition within a cell has implications in the understanding of cell metabolism, division, d ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Non-invasive method to evaluate the quality of human oocytes and embryos
SBC: Renova Life Inc. Topic: NICHDDESCRIPTION (provided by applicant): Project Summary We propose to develop a non-invasive method to predict mammalian oocyte quality by analyzing the surrounding cumulus cells' gene expression patterns (cGEP). The result of the cGEP assay---a cGEP score---can be used to predict embryo quality and ultimately the embryo transfer (ET) results. This technology, if success, will for the first time ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A user-friendly scalable microfluidic platform for enhanced neuron-cell culture
SBC: Xona Microfluidics, Inc. Topic: NIMHDESCRIPTION (provided by applicant): Neuron-cell culture is widely used for studies in basic research, drug discovery, and toxicity testing. Traditional random cultures allow limited access to subcellular compartments (axons, dendrites, synapses) due to extensive and haphazard growth of neurons. Our long-term goal is to provide robust, user-friendly, and cost effective culture platforms that can o ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Remote focusing through spatial light modulation for multifocal multiphoton micro
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NIMHDESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Piezoelectric Pump to supply Ventricular Assist Device for Fontan Patients
SBC: KINETIC CERAMICS, LLC Topic: NINRDESCRIPTION (provided by applicant): Congenital cardiovascular defects, specifically single ventricle abnormalities, constitute the most common cause of death among infants born with birth defects. Even after surgically rerouting the single ventricle circulation via the Fontan procedure, the circulation in these patients relies on blood flowing passively through the lungs. Thus, this group of pati ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health